Search
Now showing items 1-10 of 13
The use of new psychoactive substances (NPS) in young people and their role in mental health care : a systematic review
(2019-12-02)
Introduction: Over the past 10 years, a large number of New Psychoactive Substances (NPS) have entered the recreational drug scenario. NPS intake has been associated with health-related risks, and especially so for vulnerable ...
The bridge between classical and ‘synthetic’/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective
(2019-11-20)
The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new ...
New/emerging psychoactive substances and associated psychopathological consequences
(2019-07-22)
BackgroundThe present paper provides an updated review of both the large number of new/novel/emerging psychoactive substances (NPS) and their associated psychopathological consequences. Focus was here given on identification ...
New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues
(2019-04-23)
Purpose of the review: A significant increase in the number, type, and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic ...
Assessing the 2004-2018 fentanyl misusing issues reported to an international range of adverse reporting systems
(2019-02-01)
Objective: A recent, global, increase in the use of opioids including the prescribing, highly potent, fentanyl has been recorded. Due its current popularity and the potential lethal consequences of its intake, we aimed ...
Is there a potential of misuse for venlafaxine and bupropion?
(2018-03-21)
Objective: Traditionally, studies on the nonmedical use of pharmaceutical products have focused on controlled substances; e.g. opiates/opioids; and benzodiazepines. Although both bupropion and venlafaxine have been reported ...
Methoxetamine-related deaths in the UK : an overview
(2015-07-28)
Objective: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011–2013, presented at the Second International Conference on Novel Psychoactive ...
Deaths of individuals aged 16-24 years in the UK after using mephedrone
(2015-07-28)
Objective: Mephedrone is a stimulant drug chemically related to amphetamine, with effects similar to those of amphetamine and cocaine. This study aims to analyse fatalities following ingestion of mephedrone in the UK amongst ...
‘Special M’ related fatalities in the UK.
(2014-03)
Introduction: methoxetamine (MXE; ‘special M’) is a novel psychoactive substance that first appeared in 2010 as a legal alternative to ketamine and, despite now being a Class B drug, is still widely marketed via the internet ...